Cardinal Health has entered a binding letter of intent to extend its existing pharmaceutical distribution relationship with CVS Health through June 30, 2032. The agreement preserves the current scope of services, giving Cardinal longer visibility into a strategically important customer relationship. Cardinal also reaffirmed fiscal 2027 non-GAAP earnings-per-share guidance, signaling that the renewal is consistent with its existing outlook rather than a newly disclosed earnings step-up.
The company continues to expect fiscal 2027 non-GAAP EPS growth of 13% to 15%, equivalent to $12.40 to $12.60 per share. It also maintained long-term non-GAAP EPS growth guidance of 12% to 14%. Cardinal says the fiscal 2027 comparison excludes the benefit of an IEEPA tariff refund recorded in fiscal 2026, an important adjustment because including that one-time item would distort the underlying growth rate.
Why the renewal matters
Drug distribution is a scale business with large revenue volumes and comparatively thin margins. A long contract with a major pharmacy and health-services company can support purchasing leverage, network utilization and planning certainty even when the parties do not disclose the customer's revenue contribution or contract margin. Extending the relationship reduces renewal risk and lets investors focus on execution rather than the possibility of a near-term customer transition.
The absence of pricing details limits the financial conclusion. A longer term does not automatically mean better economics, and maintaining the existing service scope does not reveal reimbursement, working-capital or inflation provisions. Cardinal's reaffirmed guidance indicates that management has incorporated the renewal into its current assumptions, but it does not quantify incremental profit.
The distribution relationship also creates counterparty concentration risk. A large customer can contribute volume and bargaining leverage at the same time. Investors should watch receivables, inventory efficiency and segment profit rather than equating contract revenue with value creation.
What comes next
Cardinal plans to report fiscal first-quarter results on November 5. That update should show whether pharmaceutical demand, specialty distribution and operating efficiency remain consistent with the 13% to 15% adjusted EPS growth range. Management may also clarify the timing for converting the letter of intent into definitive agreements.
The renewal is positive because it protects continuity through mid-2032 and removes a meaningful source of uncertainty. The investment case still depends on margins, cash conversion and execution across Cardinal's broader portfolio. Without disclosed contract economics, the safest interpretation is risk reduction—not a separate earnings windfall.